Oncology Dynamics captures a substantial part of oncological patient treatment journey. It provides real world insights into how standards of care and treatment landscape differ across healthcare systems.
The purpose of this report is to provide key information and robust analyses to better optimize drug valuation, from the pharmaceutical companies perspective
Analysis of what patient services proposed by pharma companies should be. This document explains: 1. why patient centricity is essential? - 2. how to craft a patient-centric strategy? - 3. How to implement patient-centric initiatives?
Real-World Evidence: The Future of Data Generation and UsageApril Bright
As data is captured through electronic health records, registries and unique device identifiers, the generation of evidence based on this data is expected to play a crucial role in informing orthopedic manufacturers’ decisions before and after regulatory approval. While regulators, payors, hospitals and manufacturers support this shift, they acknowledge that gaps remain in its optimal execution. Priority considerations include how to generate evidence to expedite regulatory market decisions, device indication expansion, postmarket studies, postmarket surveillance and reimbursement decisions. The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), is leading the conversation with various stakeholders, including FDA and orthopedic device companies to support the sustainable generation of Real-World Evidence (RWE) using Real-World Data (RWD).
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
The global patient engagement solutions market size stood at around USD 11.8 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The market for patient engagement solutions is mainly driven by the increasing utilization of electronic health records for patient-centric care and the adoption of mobile health devices. According to a survey conducted by the NHS in 2019, approximately 92.0% of patients feel assured in self-managing treatment.
Market Drivers
Factors such as the growing burden of chronic diseases and a rise in the geriatric population have led to the adoption of patient engagement solutions worldwide. For instance, in 2017, according to CDC statistics, 1.3 million new cases of diabetes were recorded in the US alone. In response to the growing number of diabetic patients, companies are focusing on the development of patient-centric engagement solutions. For example, in June 2019, Allina Health launched a patient-centric engagement solution platform for improving the Diabetes Self-Management Education (DSME) program. This enables diabetic self-care clinical services, particularly for those located in remote locations. Moreover, programs such as these help in cost evaluation, operational effectiveness, and clinical outcomes.
Government support is expected to drive the adoption of patient engagement solutions in the coming years. For instance, in 2018, the FDA established the Patient and Caregiver Connection program. The program was aimed to foster engagement with patients, patient advocates, and caregivers throughout the evaluation and surveillance of medical devices.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
The purpose of this report is to provide key information and robust analyses to better optimize drug valuation, from the pharmaceutical companies perspective
Analysis of what patient services proposed by pharma companies should be. This document explains: 1. why patient centricity is essential? - 2. how to craft a patient-centric strategy? - 3. How to implement patient-centric initiatives?
Real-World Evidence: The Future of Data Generation and UsageApril Bright
As data is captured through electronic health records, registries and unique device identifiers, the generation of evidence based on this data is expected to play a crucial role in informing orthopedic manufacturers’ decisions before and after regulatory approval. While regulators, payors, hospitals and manufacturers support this shift, they acknowledge that gaps remain in its optimal execution. Priority considerations include how to generate evidence to expedite regulatory market decisions, device indication expansion, postmarket studies, postmarket surveillance and reimbursement decisions. The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), is leading the conversation with various stakeholders, including FDA and orthopedic device companies to support the sustainable generation of Real-World Evidence (RWE) using Real-World Data (RWD).
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
The global patient engagement solutions market size stood at around USD 11.8 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The market for patient engagement solutions is mainly driven by the increasing utilization of electronic health records for patient-centric care and the adoption of mobile health devices. According to a survey conducted by the NHS in 2019, approximately 92.0% of patients feel assured in self-managing treatment.
Market Drivers
Factors such as the growing burden of chronic diseases and a rise in the geriatric population have led to the adoption of patient engagement solutions worldwide. For instance, in 2017, according to CDC statistics, 1.3 million new cases of diabetes were recorded in the US alone. In response to the growing number of diabetic patients, companies are focusing on the development of patient-centric engagement solutions. For example, in June 2019, Allina Health launched a patient-centric engagement solution platform for improving the Diabetes Self-Management Education (DSME) program. This enables diabetic self-care clinical services, particularly for those located in remote locations. Moreover, programs such as these help in cost evaluation, operational effectiveness, and clinical outcomes.
Government support is expected to drive the adoption of patient engagement solutions in the coming years. For instance, in 2018, the FDA established the Patient and Caregiver Connection program. The program was aimed to foster engagement with patients, patient advocates, and caregivers throughout the evaluation and surveillance of medical devices.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
The introduction of Identification of Medicinal Products (IDMP), as developed by the International Organization for Standardization (ISO), marks the next phase of evolution for the European drug dictionary project under Article 57.
The European Medicines Agency (EMA) will issue guidance based on five documents published by the ISO, which will require life sciences companies to use a "set of common global standards for data elements, formats, and terminologies for the unique identification and exchange of information on medicines."
Complying with IDMP represents a massive increase in scope and complexity, in addition to previous iterations. The EMA has divided the timeline for meeting the new requirements into several phases, making this a multi-year project.
Perficient’s expert in IDMP and the EudraVigilance Medicinal Product Dictionary, Mark Thackstone, reviewed everything you need to know in order to successfully comply with IDMP by the fast-approaching deadline:
-Latest information and timelines
-Steps to take meet regulatory requirements
-Challenges and factors to consider
-What IDMP means in the real world of a typical pharma company
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
We are living in the world of “Big Data”. “Big Data” is mainly expressed with three Vs – Volume, Velocity and Variety. The presentation will discuss how Big Data impacts Pharmaceutical Industry and how drug companies can lead this new Big Data environment.
Lifecycle Management in the Pharmaceutical IndustryAnthony Russell
Presented to students in the Drug Development and Product Management program at UC San Diego. Covers the rationale for lifecycle management is important. Includes case studies of successful implementation of lifecycle management. Presentation date: 2/5/2019.
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsCognizant
Driven partly by regulatory pressure, stakeholders in the healthcare ecosystem—including payers and patients—now want real-world evidence (RWE) about wellness to supplement and expand randomized control trial (RCT) input from pharmas about pharmaceuticals' efficacy and effectiveness.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Approaches to regulatory approval and process validation often must be quite different than traditional approaches. This presentation walks through nine approaches that might be helpful to your project.
MPG Life Sciences Software Market Snapshot October 2020Madison Park Group
We are pleased to present our life sciences software market snapshot for October 2020.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna, Jonathan Adler and James Tomasullo spearhead the firm's efforts in the space.
Risk-based Monitoring Strategies for Improved Clinical Trial PerformanceCognizant
To address draft regulatory guidance for risk-based clinical trial monitoring, sponsors should consider strategies that utilize social, mobile, analytics and cloud technologies to create responsive methodologies that satisfy both the spirit and the letter of these new guidelines.
Creating value through patient support programsSKIM
How do we become more patient-centered as an organization? How do we ensure the patient/caregiver experience is as optimal as possible?
These are the questions that are being poised to healthcare market researchers in today’s healthcare landscape. And typically healthcare market researchers are turning to methods like “patient journeys” and “patient personas” to help bring that patient-centered understanding to the organization. Problem is … in order to be truly patient-centered, you need to take this charge on from the inside out.
Experience, Design and Innovation departments are springing up in all kinds of healthcare organizations intent on facilitating the organizational shift towards patient-centricity. And, unfortunately, market researchers are intentionally not being invited to the table. If history repeats itself, that will soon change though. These Experience, Design and Innovation departments will need the rigor and breadth of method knowledge that market researchers have in order to succeed in the strategic agendas of their work.
This presentation will give market researcher pointers on which skills, methods and mindsets they’ll likely need to adopt if they are hoping to be perceived as a valued contributor to an Experience, Design or Innovation team. In essence, give attendees a blueprint for how to open up a whole new professional opportunity for themselves, with a simple reframe on whom they are and what they do.
BI Consultancy - Data, Analytics and StrategyShivam Dhawan
The presentation describes my views around the data we encounter in digital businesses like:
- Looking at common Data collection methodologies,
-What are the common issues within the decision support system and optimiztion lifecycle,
- Where are most of failing?
and most importantly, "How to connect the dots and move from Data to Strategy?"
I work with all facets of Web Analytics and Business Strategy and see the structures and governance models of various domains to establish and analyze the key performance indicators that allow you to have a 360º overview of online and offline multi-channel environment.
Apart from my experience with the leading analytic tools in the market like Google Analytics, Omniture and BI tools for Big Data, I am developing new solutions to solve complex digital / business problems.
As a resourceful consultant, I can connect with your team in any modality or in any form that meets your needs and solves any data/strategy problem.
Real-World Data and Real-World Evidence Webinar
Panelists
Tara Cowling, Medlior
Laurie Lambert, CADTH
Craig Campbell, London Health Sciences
Sandra Anderson, Innomar Strategies
Brad Alyward, Canadian Organization for Rare Disorders
Durhane Wong-Rieger, Canadian Organization for Rare Disorders
The introduction of Identification of Medicinal Products (IDMP), as developed by the International Organization for Standardization (ISO), marks the next phase of evolution for the European drug dictionary project under Article 57.
The European Medicines Agency (EMA) will issue guidance based on five documents published by the ISO, which will require life sciences companies to use a "set of common global standards for data elements, formats, and terminologies for the unique identification and exchange of information on medicines."
Complying with IDMP represents a massive increase in scope and complexity, in addition to previous iterations. The EMA has divided the timeline for meeting the new requirements into several phases, making this a multi-year project.
Perficient’s expert in IDMP and the EudraVigilance Medicinal Product Dictionary, Mark Thackstone, reviewed everything you need to know in order to successfully comply with IDMP by the fast-approaching deadline:
-Latest information and timelines
-Steps to take meet regulatory requirements
-Challenges and factors to consider
-What IDMP means in the real world of a typical pharma company
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
We are living in the world of “Big Data”. “Big Data” is mainly expressed with three Vs – Volume, Velocity and Variety. The presentation will discuss how Big Data impacts Pharmaceutical Industry and how drug companies can lead this new Big Data environment.
Lifecycle Management in the Pharmaceutical IndustryAnthony Russell
Presented to students in the Drug Development and Product Management program at UC San Diego. Covers the rationale for lifecycle management is important. Includes case studies of successful implementation of lifecycle management. Presentation date: 2/5/2019.
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsCognizant
Driven partly by regulatory pressure, stakeholders in the healthcare ecosystem—including payers and patients—now want real-world evidence (RWE) about wellness to supplement and expand randomized control trial (RCT) input from pharmas about pharmaceuticals' efficacy and effectiveness.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Approaches to regulatory approval and process validation often must be quite different than traditional approaches. This presentation walks through nine approaches that might be helpful to your project.
MPG Life Sciences Software Market Snapshot October 2020Madison Park Group
We are pleased to present our life sciences software market snapshot for October 2020.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna, Jonathan Adler and James Tomasullo spearhead the firm's efforts in the space.
Risk-based Monitoring Strategies for Improved Clinical Trial PerformanceCognizant
To address draft regulatory guidance for risk-based clinical trial monitoring, sponsors should consider strategies that utilize social, mobile, analytics and cloud technologies to create responsive methodologies that satisfy both the spirit and the letter of these new guidelines.
Creating value through patient support programsSKIM
How do we become more patient-centered as an organization? How do we ensure the patient/caregiver experience is as optimal as possible?
These are the questions that are being poised to healthcare market researchers in today’s healthcare landscape. And typically healthcare market researchers are turning to methods like “patient journeys” and “patient personas” to help bring that patient-centered understanding to the organization. Problem is … in order to be truly patient-centered, you need to take this charge on from the inside out.
Experience, Design and Innovation departments are springing up in all kinds of healthcare organizations intent on facilitating the organizational shift towards patient-centricity. And, unfortunately, market researchers are intentionally not being invited to the table. If history repeats itself, that will soon change though. These Experience, Design and Innovation departments will need the rigor and breadth of method knowledge that market researchers have in order to succeed in the strategic agendas of their work.
This presentation will give market researcher pointers on which skills, methods and mindsets they’ll likely need to adopt if they are hoping to be perceived as a valued contributor to an Experience, Design or Innovation team. In essence, give attendees a blueprint for how to open up a whole new professional opportunity for themselves, with a simple reframe on whom they are and what they do.
BI Consultancy - Data, Analytics and StrategyShivam Dhawan
The presentation describes my views around the data we encounter in digital businesses like:
- Looking at common Data collection methodologies,
-What are the common issues within the decision support system and optimiztion lifecycle,
- Where are most of failing?
and most importantly, "How to connect the dots and move from Data to Strategy?"
I work with all facets of Web Analytics and Business Strategy and see the structures and governance models of various domains to establish and analyze the key performance indicators that allow you to have a 360º overview of online and offline multi-channel environment.
Apart from my experience with the leading analytic tools in the market like Google Analytics, Omniture and BI tools for Big Data, I am developing new solutions to solve complex digital / business problems.
As a resourceful consultant, I can connect with your team in any modality or in any form that meets your needs and solves any data/strategy problem.
Real-World Data and Real-World Evidence Webinar
Panelists
Tara Cowling, Medlior
Laurie Lambert, CADTH
Craig Campbell, London Health Sciences
Sandra Anderson, Innomar Strategies
Brad Alyward, Canadian Organization for Rare Disorders
Durhane Wong-Rieger, Canadian Organization for Rare Disorders
Overview about Caris Life Sciences, a biotech company headquartered in Irving, Texas USA specializing in precision medicine using tumor profiling to aid oncologists in the selection of cancer therapy.
Outcome Measures in Cancer: Do disease specific instruments offer greater sen...Office of Health Economics
Paula's slides for her presentation on Outcomes Measures in Cancer given at the C2E2 Rounds Conference at the University of British Columbia on July 5th, 2017.
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions.
The webinar was followed by an interactive question & answer session.
Geneva Pharma Forum on Pharmacovigilance: Partnering for
Patient Safety (Geneva, 20 November 2012), Jeremiah Mwangi, Director, Policy and External Affairs, IAPO
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Public Reporting as a Catalyst for Better Consumer DecisionsATLAS Conference
Greater efficiency in the process of matching patients to appropriate providers is vital to achieving the Triple Aim. As patients research and choose among appropriate providers, sound decision-making will depend on the accessibility of high-quality data that enables them to make meaningful, actionable comparisons. Online public-reporting tools, such as those published by U.S. News, CMS and others, serve as venues for consumer decision-making. Driven by current trends in data transparency, rapid advances in public reporting can be anticipated. This presentation will outline several recent and expected future developments in the evolution of key public-reporting tools, and discuss their role in facilitating patient engagement and access to appropriate care.
Rare Disease Patient Registries:
Key to Drug Development and Access
Tuesday, May 3 @ 12:00 – 1:00 pm EDT
Slides:
USA National Institutes of Health RaDaR
NORD IAMRARE (Pam Gavin, VP)
Canada INFORM RARE (Beth Potter, CHEO; Pranesh Chakraborty, CHEO; Kim Angel, Can MPS Society; John Adams, CanPKU)
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
2. 1
Meaningful insights based on large real-world data sources and advanced analytics. Robust
evidence to support treatments. A clearer picture of the patient journey. And insights that actually
lead to better commercial performance.
Oncology expertise powered by real-world insights
IQVIA Global Oncology Capabilities *Evaluate Pharma 2016
3. 2
The three hurdles of high-quality
oncology data delivery:
1. Identifying and accessing
reliable and rich data sources
2. Finding solutions to secure,
cleanse, and structure the data
3. Deriving meaningful insights and
evidence from the data at hand
The oncology data-to-insights ecosystem is simple to define but
complex to deliver
IQVIA Global Oncology Capabilities
Oncology Dynamics: Survey data that
provides easy access to rich, structured,
multi-country, oncology anonymous
patient-level insights
4. 3
Oncology Syndicated Solutions in IQVIA
• Larger sample and panel size overall
• Covers all cancers
• Predefined focused questionnaire
• Current treatment + most recent prior treatment
• Sample and projected data
• Data reported from medical records
• Covers specific cancer sub-type, stage or line of therapy
• Predefined detailed questionnaire
• Full treatment history
• Sample data
• Data reported from medical records
• Specific questions related to cancer types, treatment, patients,
outcomes, healthcare resource use, physician perception
• Customized questionnaire
• Sample data
• Data can/cannot be reported from medical recordsAn international team dedicated to optimal study design,
fieldwork, panel management, data collection, reporting
Oncology
Dynamics,
including OD
Boosts
Customised
Market
Research & PI
2
4
3
Oncology
Advantage
Oncology
Diagnosis
Insights
1 • All cancers, all stages, all lines of therapy
• Co-diagnosis related to certain supportive care treatments
• Specialties identified to be involved in the active treatment
• Prescription information (diseases, biomarkers, drug
treatment, patient profile, prescriber)
Oncology Diagnosis Insights
5. 4
What type of questions can be answered with the aid of OncoDynamics…
Interested in the up-to-date clinical and treatment information
within oncology?
IQVIA Global Oncology Capabilities
Market Dynamics in Breast Cancer
Patient Profiling and Treatment Patterns in Liver Cancer
Treatment Landscape in Ovarian Cancer
Treatment Patterns in Pancreatic Cancer
Biomarker Testing Rates and Impact on Treatment Decisions in
NSCLC
Market Dynamics for select Supportive Therapies
Standard of care in Acute Myeloid Leukemia
6. 5
EVALUATE
Current Standard
of Care
UNDERSTAND
Patient profiles &
sub-populations
EXAMINE
Drug Utilization &
Treatment
Patterns
BENCHMARK
Adherence to
Clinical Guidelines
INFORM
Study Protocols &
Feasibility
QUANTIFY
Cost of Drug
Therapies
Interrogate our syndicated patient database with little lead time and effort – Oncology Dynamics
Oncology cross-sectional surveys can address many RWE
questions – from strategy development to post-launch
IQVIA Global Oncology Capabilities
7. 6
Key business questions
How do healthcare stakeholders use oncology survey data
today?
IQVIA Global Oncology Capabilities
Business
Intelligence
Team
HEOR
Team
Pipeline &
BD Team
Market
Access
Team
Brand
Team
Clinical
Operations
& Study
Teams
____________________
How does the patient journey and
standard of care differ across countries?
____________________
How is the testing rate for key biomarkers
evolving over time?
____________________
Which patient populations are underserved
with effective therapies?
____________________
How is the competitive landscape evolving?
____________________
How is my brand being used
in the real-world setting?
____________________
Does my clinical study protocol reflect
real-world populations and clinical practice?
8. 7
Geographies
Variables
Diseases
Physician
specialties
+ Europe: France, Germany, Italy, Spain, UK, Romania. Belgium coming in Q2
2020.
+ Americas: Mexico, Brazil
+ Asia: Japan, China, South Korea, Saudi Arabia
+ Drug-treated cases of all cancers are collected at natural fallout and
projected to treated prevalence. A selection of key cancers are available in
Romania, Mexico, Brazil, and Saudi Arabia.
+ All drug-treating physician specialties working with oncology patients
+ Patient and clinical characteristics, including staging and biomarker status
+ Current and most recent previous drug treatments, including chemotherapy,
immunotherapy, endocrine and targeted therapies
+ Current supportive therapy
+ Indication-specific parameters
Features &
coverage
All patient data are de-identified and comply with relevant rules for patient privacy protection
Oncology Dynamics is a cross-sectional survey that collects
patient-level data from a representative panel of physicians
9. 8
The Oncology Dynamics survey can be carried out in other countries
Interested in new geographies?
• A dedicated international fieldwork team operating in
over 20 countries
• A large and stable panel of oncologists and cancer
treating specialists participating to multiple IQVIA
studies
• A global and standard methodology applied across
all countries
• A syndicated questionnaire applicable to most countries
*Europe: 5EU, Austria, Belgium, Denmark, Ireland, Netherlands, Poland, Russia, Sweden; Americas: Brazil, Canada, Mexico; APAC: Australia, China, Japan, South Korea, Taiwan, Philippines
Over 10 years experience in conducting
international syndicated & customised
oncology survey based studies
Over 100 customised cancer-specific
surveys conducted in last 10 years
Data collected for over 20 countries*
10. 9
Easily access rich, structured, multi-country, oncology
anonymous patient-level data
Compare KPIs across tumour types, drugs, and countries
through a consistent methodology
Make confident decisions based on data from a stable
and representative source
Derive insights and understand trends in cancer care
• 150,000+ patient cases
collected each year
• 1,500+ specialists per year
• Statistically driven study
design
• Consistent methodology
applied across all
countries
• Frequent updates
The product enables healthcare stakeholders to…
Oncology Dynamics is a syndicated survey collecting
comprehensive and clinically relevant oncology patient data
IQVIA Global Oncology Capabilities
11. 10
No derived
variables
No data period
gap
Capture & measure
unobservable data
(e.g. line of therapy,
drug preference)
Collect same data
parameters from
different sites
Structured data
Collect standardized
measures
Regular updates
Easy to query
Simple to
analyse
Consistent
comparison
across healthcare
settings and
providers
No derived
variables
Relatively free
from several
types of errors
Structured, Easy to Access, Consistent, Up-to-date
Key Features of Oncology Dynamics Data
IQVIA Global Oncology Capabilities
12. 11
Four Key Characteristics of the Oncology Dynamics Offering
IQVIA Global Oncology Capabilities
Fully
Anonymised
Patient Data Secondary
Data
Market
Research
Survey
Syndicated
Data are fully anonymised and no patient identifier
is collected. Comply with personal data protection
regulation GDPR Regulation EU 2016/679
No primary data is generated or
collected. Reporting of individual
Adverse events is not required
(EMA Guideline on Good
Pharmacovigilance Practices
GVP Module VI - Management
and reporting of adverse
reactions to medicinal products)
Information is collected to
satisfy multiple clients’ needs.
Hence, it is not required to
follow PMR regulations.
Comply with the market research code of
conduct (EphMRA Code of Conduct 2017)
(Regulation of the European
Parliament and the Council
on the Protection of
individuals with regard to the
processing of personal data
and on the free movement of
such data)
13. 12
Patient records are
collected during consultation
Data are transmitted
to IQVIA and processed
QuestionnairePatient record Clients
Physicians fill in
the online questionnaire
Data are delivered to clients
via applications and reports
Snapshots of medical records are reported by the physician through a web-based questionnaire
Data collection methodology
IQVIA Global Oncology Capabilities
IQVIA
• Large and stable panels of physicians participating in multiple IQVIA studies
• Fieldwork and data collection managed by a dedicated international team
Over 400 quality controls are conducted during each data production cycle
14. 13
Physicians and cases are selected based on specific criteria
IQVIA Global Oncology Capabilities
*Physicians surveyed are enrolled in the IQVIA One Key & MEBOS panel (representing >80% of the universe).
**Hospitals physicians in France, Italy, Spain, UK, China, South Korea, Japan. Hospital and office-based specialists in Germany.
***The consecutive order of cases collected ensures a random un-biased collection of cases. This criteria does not apply to Saudi Arabia
Case selection criteria
• Patients with a current diagnosis of cancer (any stage)
• Patients currently receiving any cytotoxic therapy, targeted therapy, gene therapy, hormonal or immunotherapy
• First consecutive cases personally treated by the surveyed physician during the reporting period (length of period
depending on the country) up to a maximum defined number of cases***
Panel selection criteria*
• Clinicians must have personally drug treated cancer patients during the last reporting period (length of period
depending on the country)**
• Targeting a maximum of 3 clinicians from the same hospital in order to avoid any cluster effect and potential
duplication of patients
15. 14
OncoDynamics captures a substantial part of the oncological
patient treatment journey
IQVIA Global Oncology Capabilities
Time
Current Disease Status
ECOG, current stage/grade
May 2017
Current drug treatment
Regimen, line of therapy,
planned duration, dosage, cycles
Demographics & Clinical Characteristics
Age, gender, smoking status, comorbidities
Most recent prior drug treatment
Regimen, duration,
Cycles given, side effects
Oncology Dynamics relies exclusively on the usage of secondary data and no primary data is generated or collected. As per EMA Guideline on Good
Pharmacovigilance Practices (GVP) Module VI, “Management and reporting of adverse reactions to medicinal products”, the offering does not require search or
reporting of individual Adverse events or any other special reporting situation
Jan 2019
Surgery
Initial diagnosis (histology, cancer type, stage& grade)
Tests (chromosomal abnormalities, biomarkers)
Current treatment start dateMost recent previous treatment start date
Survey time
16. 15
Many of the key cancer-specific variables are collected in
Oncology Dynamics
Current drug therapy
– Molecule & regimen
– Line of therapy
– Planned duration and dosing
Most recent prior drug therapy
– Molecule & regimen
– Line of therapy
– Duration
– Side effects
– Reason for discontinuation
Non-drug therapy
– Surgery
– Radiotherapy
– Stem cell transplant
Supportive therapy
– Anti-emetics
– Growth factors
– Erythropoietins
– Bone-targeted agents
Core information
– Cancer type
– Histology
– Stage/grade at diagnosis
– Stage/grade at current treatment
– Relapse/progression
– Date of diagnosis
– Gender
– Age
– Smoking status
– Clinical trial enrolment
– ECOG status & comorbidities
Tumour-specific attributes
– Hormone refractory status (prostate)
– PSA level (prostate)
– Platinum status (ovarian)
Tumour-specific biomarkers & tests
– Time of test (e.g. at diagnosis)
Therapy initiator specialty
Treatment perception
– Overall therapy satisfaction
– Treatment alternatives considered by the
physician
Measure AttributesTHERAPY ASPECTS
PATIENT PROFILE
PHYSICIAN ATTRIBUTES
17. 16
Robust sample size for most key cancers across all countries
Global Cancer Coverage in Oncology Dynamics
IQVIA Global Oncology Capabilities
*MAT Q3 sample counts provided where possible, estimates provided otherwise
**Italy: sub-regional data collection requiring larger sample than other countries
***Semesterly collection
Country
Hem.
Cancers
M.
Myeloma
Breast NSCLC Prostate CRC Bladder Kidney Stomach Pancreas Ovarian Liver Melanoma
Head &
Neck
SCLC
Other
Cancers
Annual
count*
France 2,950 890 3,399 2,252 2,282 1,497 824 1,056 222 763 495 487 413 802 118 2,036 20,486
Germany 3,369 810 3,195 2,438 4,778 1,827 2,024 1,626 473 981 696 340 1,135 305 458 2,580 27,035
Italy 7,162 1,549 3,725 4,103 3,304 3,153 2,231 1,359 674 1,112 1,409 650 929 778 619 2,895 35,652**
Spain 4,663 1,228 2,452 1,875 2,163 1,650 1,212 945 260 604 403 228 520 590 264 2,895 21,952
UK 3,142 756 2,730 2,311 2,621 1,383 1,296 1,047 298 634 496 306 818 551 345 3,018 21,752
China 1,567 367 2,150 3,588 530 2,616 465 266 1,280 407 651 943 31 683 504 1,950 17,998
Japan 946 195 1,352 2,330 1,463 1,468 174 402 1,449 730 299 778 238 214 157 1,018 13,213
South Korea 822 159 696 756 467 769 54 85 637 150 313 536 22 66 104 634 6,270
Mexico
1,072
ALL, CML,
CLL, NHL
196 1,924 359 1,236 641 277 476 — 205 416 — 131 — — — 6,933
Saudi
Arabia***
Yes
(NHL)
New 2019 Yes Yes — Yes —
RCC New
2019
— — — — — — Yes — ~2,060
Romania — Yes Yes Yes Yes Yes — — — — Yes — Yes — — — ~4,300
Brazil
CML, NHL,
AML, CLL
Yes Yes Yes Yes Yes Yes Yes — Yes Yes — Yes — — — ~6,180
18. 17
Cancer-specific diagnostic and prognostic biomarkers are
collected for solid cancers
IQVIA Global Oncology Capabilities
Solid tumours
Available
from
Bladder Brain Breast
Bronchus &
Lung
Cervix Uteri Colorectal Corpus Uteri GIST* Head & Neck Kidney Liver
ALK 2016 l
BRAF 2016 l
BRCA1/2 2016 l
BRCA origin Q1 17 l
BRCA1/2 test performed Q1 2018 l
Circulating Tumour Cells 2016 l l l
C-KIT 2016 l
C-MET 2016 l l l l l
Current PSA 2016
EGFR
2016
(GBM Q1 17) l l l
EGFR test performed Q1 2018 l l
FGFR 2016 l l l
NOTE: Not all biomarkers are collected in Italy for the cancers listed above
*NEW indication
l Mutation
KEY l Over expression / elevated / gene amplification
l Other
19. 18
Cancer-specific diagnostic and prognostic biomarkers are
collected for solid cancers
IQVIA Global Oncology Capabilities
Solid tumours
Available
from
Bladder Brain Breast
Bronchus &
Lung
Cervix Uteri Colorectal Corpus Uteri GIST* Head & Neck Kidney Liver
HER2 status 2016 l
Hormone receptors ( ER and PR) 2016 l
TNBC 2016 l
Ki-67 antigen level 2016 l l
K-RAS 2016 l l
Microsatellite instability
All tumours from
Q3 17
l l l l l l l l l l l
Mitotic index 2016 l l
N-RAS 2016 l
PD1/ PD-L1/PD-L2
Q4 2016
all tumours
collected from
Q1 18
l l l l l l l l l l l
PIK3CA Q1 2019 l l
Platinum status 2016 l
RET rearrangement Q3 17 l
ROS-1 gene alteration Q3 17 l
tp53 mutation Q3 2019
TRK expression Q2 2019 l l l l l l l l l l l
Tumour Mutation Burden (TMB) Q1 2019 l l l l l l l l l l l
NOTE: Not all biomarkers are collected in Italy for the cancers listed above
*NEW indication
l Mutation
KEY l Over expression / elevated / gene amplification
l Other
20. 19
Cancer-specific diagnostic and prognostic biomarkers are
collected for solid cancers
IQVIA Global Oncology Capabilities
Solid tumours
Available
from
Melanoma NSCLC Oesophagus Ovarian Pancreas Prostate SCLC Stomach Testis Thyroid
ALK 2016 l l
BRAF
2016
(NSCLC Q4 16 )
l l
BRCA1/2 2016 l l
BRCA origin Q1 17 l
BRCA1/2 test performed Q1 2018 l
Castration-resistant 2016 l
C-KIT 2016 l l
C-MET 2016 l l l l l l
Current PSA level 2016 l
Circulating Tumour Cells 2016 l l l
EGFR
2016
(GBM Q1 17)
l l
EGFR Type of mutations
(Exon19Del, L858R, T790M
Q2/Q3 17 l
NOTE: Not all biomarkers are collected in Italy for the cancers listed above
l Mutation
KEY l Over expression / elevated / gene amplification
l Other
21. 20
Cancer-specific diagnostic and prognostic biomarkers are
collected for solid cancers
IQVIA Global Oncology Capabilities
Solid tumours
Available
from
Melanoma NSCLC Oesophagus Ovarian Pancreas Prostate SCLC Stomach Testis Thyroid
FGFR 2016 l l l
Gleason Score 2016 l
HER2 status 2016 l
Ki-67 antigen level 2016
K-RAS 2016 l l l
Microsatellite instability from Q3 17 all
solid tumours
l l l l l l l l l l
Mitotic index 2016
N-RAS 2016 l
PD1/ PD-L1/PD-L2
Q4 2016
all tumors
collected from
Q1 18
l l l l l l l l l l
Platinum Status 2016 l
RET rearrangement 2016 l l
ROS-1 gene alteration 2016 l l
tp53 mutation Q3 2019 l
TRK expression Q2 2019 l l l l l l l l l l
Tumour Mutation Burden (TMB) Q1 2019 l l l l l l l l l l
NOTE: Not all biomarkers are collected in Italy for the cancers listed above
l Mutation
KEY l Over expression / elevated / gene amplification
l Other
22. 21
Indications added in Q1 2018
Cancer-specific diagnostic and prognostic biomarkers are
collected
IQVIA Global Oncology Capabilities
Cancers Available from
Connective & Soft
Tissue
Gall Bladder GIST Mesothelioma NETs
Myelodysplastic
Syndromes
C-KIT Q1 2018 l
Ki-67 antigen level Q1 2018 l l
Microsatellite instability Q1 2018 l l l l l
Minimum residual disease Q2 2019 l
Mitotic index Q1 2018 l l l
PD1/ PD-L1/PD-L2 % expression Q1 2018 l l l l l l
TRK expression Q2 2019 l l l l l
Tumour Mutational Burden (TMB) Q1 2019 l l l l l l
NOTE: Not all biomarkers are collected in Italy for the cancers listed above
While we might have back data for these indications , we will not have all biomarkers in these indications –
these have been created as new indications in Q1 2018 so biomarkers will be aligned from then.
l Mutation
KEY l Over expression / elevated / gene amplification
l Other
23. 22
The sample can be boosted for a tumor, subpopulation, and lines of therapy of choice
Additional ovarian cancer and melanoma patients are collected
each quarter to ensure a robust sample in later lines of therapy
IQVIA Global Oncology Capabilities
Custom OD Boost
• Population of interest
• Select lines of therapy
Running Boost: Melanoma
• Advanced or metastatic stage
• 2nd and 3rd+ lines of therapy
• EU5: since Q1 2019 and running
Running Boost: Ovarian cancer
• Advanced or metastatic stage
• 2nd and 3rd+ lines of therapy
• EU5: since Q2 2018 and running
Oncology
Dynamics
24. 23
Drug-treating specialties contributing to the Oncology Dynamics survey
Global Panel Coverage in Oncology Dynamics
IQVIA Global Oncology Capabilities
Specialties* France Germany Italy Spain UK Japan China South Korea Mexico
Saudi
Arabia
Romania
New for 2019
Brazil
New for 2019
Dermatology
ENT
GI medicine
Gynecology
Hematology
Hepatology
Oncology
Pulmonology
Radiotherapy
Urology
Surgery
Total** 231 246 475*** 222 221 418 750 130 102 45 76-81 73-91†
*Specialty distribution design derived from findings of a large IQVIA survey conducted in 2015 & 2017
**Quarterly targets for 2019
***Large panel due to sub-regional offering available in Italy
†Q2–Q3 2019 range
25. 24
Oncology Dynamics data are projected based on a robust
projection methodology
IQVIA Global Oncology Capabilities
Sample patients are projected to an aggregated annual treated prevalence figure at the key cancer and
specialty level within country.
Physicians Patient Prevalence
Physician Universe Treated Prevalence
The number of physicians in the panel
is projected to the universe for that
specialty
The number of patients treated by
the physicians in each specialty is
projected to the universe to provide
national prevalence in each cancer
and country
*A large study conducted in 2015 & 2017. Data from a large sample of nearly 5,000 physicians across all specialties were collected to evaluate the prevalent
treated population and the specialties treating cancer patients. The study was conducted in France, Germany, Italy, Spain and the UK.
• The IQVIA Physician Universe Study* is used to define the right mix and weighting of specialties which allows more accurate
projections to market level
• The projection methodology takes into account varying workload levels of participating physicians
OD Physician Panel OD Physician Workload
26. 25
Type of Facility by Country
G5 EU Sample Base: 891 Facilities
72%
29%
90%
85%
97%
15%
13%
8%
10%
15%
3%
63%
155 202 263 143 128
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
France Germany Italy Spain U.K.
PUBLIC PRIVATE NO PROFIT PRIVATE OFFICE BASED PRACTITIONER
27. 26
Status of Facility by Country
G5 EU Sample Base: 891 Facilities
65%
22%
82%
34% 36%
35%
14%
18%
66% 64%63%
155 202 263 143 128
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
France Germany Italy Spain U.K.
Non University University Office Based Practitioner
29. 28
Facilities by Country
G4 EU Sample Base: 736 Facilities
12%
7% 8%
11%
23%
63%
88%
61%
1%
30%
4%
28%
63%
202 263 143 128
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Germany Italy Spain U.K.
CANCER HOSPITAL MAIN CANCER UNIT NO CANCER UNIT OFFICE BASED PRACTITIONER
32. 31
While oncologists are the main therapy initiations for
gastroenteropancreatic neuroendocrine tumors treatment in EU5,
surgeons take the lead in Benelux
-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65
-10
-5
0
5
10
15
20
30
35
40
45
50
55
60
65
Benelux
Oncologist
Surgeon
EU5
Endocrinologist
Gastroenetrologist
Illustrative (dummy data)
33. 32
Therapy initiators for Somatuline by ICD-10 indication in the UK&I
C7A.020 C25.8 C26.9
OncologistsPulmonologists
Onco-Haematologists
Radiotherapists
Dermatologists Endocrinologists
Illustrative (dummy data)
34. 33
Interesting findings published in the medical domain using
Oncology Dynamics data
IQVIA Global Oncology Capabilities
NSCLC pts with brain metastases are not
treated as expected (lack of guidelines, no
clinical trial data available). Abstract accepted
at American Oncology conference 2018
Unexpected immune related side
effects for innovative targeted
therapies. Presented at European
Oncology Conference 2017
35. 34
Deliverables
IQVIA Global Oncology Capabilities
• Dataview database
– Allows advanced data manipulation and groupings
• OD Easy Access: Web-based Microstrategy® application.
– Core application with pre-defined reports
Syndicated
• Customised reports
– Developed to meet specific clients’ needs: Excel,
PowerPoint, customized dashboards that can be built
using the Microstrategy Visual Insights solution
• OD Custom View:
– Customised analyses based on parameters not included
in Dataview or in the web-based application e.g. time gap
analysis, treatment duration, dosing, multi-variables
patient profiling analysis, volume use by indication,
more…
Customised
36. 35
For further information, please contact:
Weronika Ficek
Business Development Specialist, Secondary Care Solutions
+44 7880 378081
Weronika.Ficek@iqvia.com
Thank you
Editor's Notes
5 min analysis, 30 min formatting
5 min analysis, 30 min formatting
Data Used: Diagnosis Insights, December 2015
Analysis: Chart data included for New, Switch , Repeat bar chart, person indicated in sections
Contact: Claude Herinckx, Dir, Offering Development, RWES
Best Practice Recommend: Product positioning is about patients first. Analysis of market dynamics and future market potential allows companies to size the addressable market, identify opportunities and understand the potential place for an agent, new or existing, in the patient journey.